Lipoprotein, Very Low Density

Athens Research

Lipoprotein, Very Low Density

9

Cardiovascular Disease, Diabetes

Research Use Only

≥ 95% by electrophoresis

Very low-density lipoprotein (VLDL) is a triglyceride-rich lipoprotein synthesized and secreted by the liver, with typical fasting concentrations ranging from 0.5 to 2.0 g/L. VLDL’s primary function is to transport endogenous triglycerides, cholesterol, and other lipids from the liver to peripheral tissues, where they are either utilized for energy or stored. Structurally, VLDL contains apolipoprotein B-100, which is essential for its assembly, secretion, and recognition by cellular receptors. As VLDL circulates, it interacts with enzymes such as lipoprotein lipase, which hydrolyzes its triglycerides, transforming VLDL into intermediate-density lipoprotein (IDL) and eventually low-density lipoprotein (LDL). Beyond lipid transport, VLDL influences vascular function by modulating nitric oxide signaling and stimulating aldosterone synthesis, affecting blood pressure regulation. Elevated VLDL levels are linked to atherosclerosis, coronary artery disease, metabolic syndrome, and type 2 diabetes, especially when large or electronegative VLDL subclasses are present. Clinically, VLDL measurement aids in cardiovascular risk assessment and research into lipid metabolism and cardiometabolic disorders.

more then 6 months from the production date.

Prepared from fresh, non-frozen plasma shown to be non reactive for HBsAg, anti-HCV, anti-HBc, and negative for anti-HIV 1 & 2 by FDA-required tests.

+2 - 8° C

12352202